ReviewFrontiers in immunology2026
The transformative impact of ultra-rapid nanopore sequencing in precision medicine.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nanopore sequencing has emerged as a transformative technology, offering unprecedented speed, ultra-long reads, and portability at a comparatively low cost. These attributes are fundamentally reshaping clinical diagnostics and personalized medicine. This review synthesizes the technological advancements driving nanopore sequencing and elucidates its pivotal applications in time-sensitive areas such as HLA matching in transplantation, infectious disease management, pharmacogenomics, and oncology. Nanopore sequencing also enables comprehensive characterization of immune-related genomic variation including HLA, KIR, LILR, Fc receptor loci, immune regulatory variants and epigenetic features. We explore the profound impact of real-time genomics on patient care, emphasizing the potential for point-of-care testing, the acceleration of clinical decision support, and the realization of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.